• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAB

PATRYS LIMITED - News & Media

0.00% ! 0.2¢
Market Cap $4.731M  !
Healthcare Biotechnology
Add to My Watchlist

Patrys Limited is focused on the development of its deoxymab platform of cell-penetrating... Patrys Limited is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, both have improved activity over the original deoxymab 3E10 antibody. PAT-DX1 is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, while PAT-DX3 is a full-sized IgG antibody. In a range of pre-clinical studies, PAT-DX1 has shown an ability to kill cancer cells in cell models, human tumor explants, xenograft and orthotopic models. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. This allows specific delivery of cancer drugs to multiple types of cancer.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Articles & Videos

Patrys (ASX:PAB) shares tumble as PAT-DX1 cancer treatment trial gets pushed back

Patrys (ASX:PAB) has flagged delays to the phase one clinical trial of its PAT-DX1 compound after a "sporadic issue" was raised by its contract development manufacturing organisation (CDMO).

31 Mar 2023 15:08 (AEDT)

Patrys (ASX:PAB) flags "synthetic lethality" potential of PAT-DX3 cancer treatment

Patrys (ASX:PAB) has claimed a recent pre-clinical study of its PAT-DX3 drug showed the product could treat cancer through "synthetic lethality" strategies.

14 Mar 2023 14:42 (AEDT)

Patrys (ASX:PAB) receives $3.35m R&D tax incentive refund

Patrys (ASX:PAB) subsidiary Nucleus Therapeutics has received a $3.35 million research and development (R&D) tax incentive refund for the 2021/2022 financial year.

30 Jan 2023 14:37 (AEDT)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
0.2¢ 		Change
0.000(0.00%) 		Mkt cap ! $4.731M
Open High Low Value Volume
0.2¢ 0.2¢ 0.2¢ $3.509K 1.754M

Buyers (Bids)

No. Vol. Price($)
46 104890723 0.1¢
 

Sellers (Offers)

Price($) Vol. No.
0.2¢ 54489518 26
View Market Depth
Last trade - 16.10pm 30/07/2025 (20 minute delay) ?
Last
0.2¢ 		  Change
0.000 ( 0.00 %)
Open High Low Volume
0.2¢ 0.2¢ 0.2¢ 39007
Last updated 15.27pm 30/07/2025 ?
PAB (ASX) Chart

Top Stories

Haranga jumps +7% on Lincoln acquisition

Haranga Resources (ASX:HAR) has spiked in intra-day trade after closing the acquisition of the Lincoln Gold Project in California.The Lincoln Project traverses 322 hectares and covers a strike length of the Mother Lode with 5.8km between Sutter Creek and Amador City. It boasts a gold resource of ...
HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic Let’s check in with what HotCopper users are closely watching at lunchtime. Given that we’re basically on the deadline before companies get a scolding if they don’t report updates, on Wednesday, the ASX announcements list is basically one big wall o...
Ionic Rare Earths falls -7% as momentum slips on vague production update Ionic Rare Earths (ASX:IXR) @ a well-known and much-loved rare earths darling on something of a comeback run lately @ has slipped -7%, presumably as the market digests what a vague update released on Wednesday actually means. According to the company, @urgent supply requests from US, European and...
Neurizon inks $1.5M loan against R&D Tax Rebate Neurizon Therapeutics (ASX:NUZ) retreated in intra-day trade on Wednesday after inking a non-dilutive loan agreement for $1.5 million to fund its current and future operations seeking to treat Huntington’s with its flagship drug NUZ-001.The funds in question are secured against it...
ASX Market Close: Index rebounds as investors buoyant | July 30, 2025 The ASX200 rebounded today and was in the green heading into the close. Investors were buoyant in response to positive inflation data that increased the odds of an interest rate cut in August.Staples, Real Estate and Discretionary were the strongest performing sectors. Utilities and IT were a dra...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.